CDK4/6 inhibitor BPI-1178

{
  "id": "MLC-T-ONC-012457",
  "term": "CDK4/6 inhibitor BPI-1178",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable selective inhibitor of cyclin-dependent kinase (CDK) types 4 (CDK4) and 6 (CDK6), with potential antineoplastic activity. Upon oral administration, CDK4/6 inhibitor BPI-1178 selectively targets and inhibits CDK4 and CDK6, which inhibits the phosphorylation of retinoblastoma protein (Rb) early in the G1 phase, prevents CDK-mediated G1-S-phase transition and leads to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of both cell cycle progression from the G1-phase into the S-phase and tumor cell proliferation. BPI-1178 may be able to penetrate through the blood-brain barrier (BBB).",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cdk4-6-inhibitor-bpi-1178/"
}